Q3 2026 Biotech Catalyst Calendar: Historical Targets and Date Checks
An archived Q3 2026 catalyst review. Separate sourced historical PDUFA targets, later company announcements and unverified dates; registry completion is not a confirmed readout.
Archived quarter: what this page can establish
Q3 2026 ended September 30. This is a historical review, not a current upcoming-event list. The July 19 publication date is preserved. This October 12 correction adds original announcement links, distinguishes targets from subsequent reports and withdraws dates that this review cannot verify.
A target action date, an observed regulatory decision and a sponsor's planned results announcement are different events. Keep the event identity, source date and later changes together. An old target does not establish that an approval occurred on that day or predict a share-price reaction.
For a present research question, inspect the current PDUFA calendar and the original record behind the particular event. A calendar entry alone does not prove current coverage or an outcome.
Choose a company and prepare a question. Run it manually after confirming the question and reviewing the required credits.
Prepared research question
Q3 2026 Biotech Catalyst Calendar: which company evidence supports or challenges the article?
Traceable citations · Unknowns marked
Review of entries in the earlier article
The table records what the cited announcement supports. It is not a complete Q3 calendar or a confirmation of every candidate's current regulatory status.
| Earlier article entry | Dated original evidence | What to retain |
|---|---|---|
| Capricor / deramiocel | March 10 announcement reported an August 22, 2026 target. August 24 update reported its extension to November 22, 2026. | Preserve both announcements. The earlier Q3 target was superseded; the later target is not proof of an outcome. |
| Ultragenyx / DTX401 | February 23 announcement reported an August 23, 2026 target. | A sourced historical target. This review does not establish the subsequent decision or current application status: UNKNOWN here. |
| Ionis / zilganersen | March 23 announcement reported a September 22, 2026 target. September 3 announcement reported FDA approval. | Keep the target and the subsequent company-reported approval separate. Do not describe the old target as still upcoming. |
| Outlook / ONS-5010 | No original target-date announcement was independently verified in this review. | The earlier specific date is withdrawn; target and current status remain UNKNOWN here. |
| Praxis / relutrigine | No original target-date announcement was independently verified in this review. | The earlier specific date is withdrawn; target and current status remain UNKNOWN here. |
The absence of a verified source in this review is not evidence that an event did not occur. It is a boundary on what this page can support. Use the latest original regulatory or sponsor disclosure to investigate a present decision.
What was knowable at the original calendar date?
A retrospective correction must not turn later information into evidence available on July 19. For the Capricor entry, the March 10 disclosure supports the historical target; the August 24 disclosure is a subsequent update. The later announcement explains why the target was superseded, but it cannot validate a forecast made before that announcement existed.
Keep two views of the same event rather than overwriting the history:
| View | Evidence cutoff | Question it can answer |
|---|---|---|
| Historical calendar | Sources published by the July 19 article date | What target had been disclosed at that time? |
| Retrospective review | The specific later disclosures inspected in this October 12 revision | Which target changed, or which decision was subsequently reported? |
| Present company research | Latest original records obtained for that request | What is the current application status? |
This page supplies the first two views only. Its source checks do not establish that all later announcements have been collected. Preserve the announcement's date, the event date it describes and the review cutoff as separate fields. If a later decision source is unavailable, record UNKNOWN; an elapsed target date does not fill that gap. This distinction also keeps a past calendar from becoming an unsupported current screen.
A trial completion date is not a readout announcement
The earlier version inferred clinical readout windows from registry completion dates. Those month-level forecasts and the unsupported totals of expected Phase 2/3 readouts have been removed.
When reviewing a ClinicalTrials.gov record, preserve the study identifier, date-field name, estimated/actual designation and update date. Keep primary completion, study completion and any posted results as distinct observations. None alone establishes a sponsor's planned public topline-announcement date.
A proposed readout window needs a dated original disclosure that actually discusses results timing. If the sponsor announcement and registry differ, retain both observations and explain their different meanings. Do not choose the more convenient date or convert an estimate into a confirmed event.
The trial-status checklist explains how to inspect a record. The PDUFA guide helps separate review targets and outcomes.
Build a dated question before running research
For one company, list the claimed event, historical source, later source, unresolved conflict and the question you need answered. An evidence table should let another reader distinguish a past target from an actual decision and an estimated trial milestone from a planned announcement.
If funding matters to that question, use the cash-runway worksheet. A catalyst date does not establish financing sufficiency, investment merit or a regulatory result.
Use this page's existing research entry to choose a company and request that dated evidence comparison. Review the proposed question before running. This archive supplies background for investigation; it does not automatically run research or replace current primary records.
Get FDA Regulatory & PDUFA Catalyst Alerts
Follow upcoming PDUFA target action dates, AdCom schedules, and review milestones with primary-source citations.
Related Articles
Crossover Confounding in Phase 3 Trials: ITT, RPSFT, and IPCW Survival Math
Audit treatment switching and crossover confounding in Phase 3 oncology survival trials across ITT, RPSFT, and IPCW methods under FDA ODAC review standards.
FDA Pre-Approval Inspections (PAI): Form 483 vs OAI and Warning Letters
Differentiate FDA Pre-Approval Inspection Form 483 observations, OAI classifications, and Warning Letters to audit CDMO manufacturing CRL risk in SEC filings.
FDA Post-CRL Resubmissions: Type A Meetings and Class 1 vs Class 2 Clocks
Model FDA post-CRL NDA and BLA resubmission timelines: Type A vs Type B meetings, 2-month Class 1 vs 6-month Class 2 PDUFA clocks, and SEC 8-K verification.